Patient Dropouts, Other “Missing Data” To Be Addressed In FDA Guidance
Executive Summary
FDA hopes two guidances - one on non-inferiority margins and another on how to handle missing data in clinical trials - will better direct industry in developing clinical trials and extrapolating more accurate data
You may also be interested in...
Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data
A new National Academy of Sciences' report on missing clinical trial data is expected to lead to significant changes in how industry sponsors design and conduct studies and statistically account for the effects of drop-outs
Industry, FDA Face Changes In Handling Of Missing Clinical Trial Data
A new National Academy of Sciences' report on missing clinical trial data is expected to lead to significant changes in how industry sponsors design and conduct studies and statistically account for the effects of drop-outs
Statistics Bedeviled Cymbalta Fibromyalgia NDA, Derail Chronic Pain Claim
The statistical dispute behind Lilly's withdrawal of its chronic pain sNDA for Cymbalta should come as no surprise to the sponsor - the issue was previewed during FDA's review of an earlier duloxetine indication, fibromyalgia